BC
MREO

Birchview Capital’s Mereo BioPharma MREO Stock Holding History

Birchview Capital’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-77,570
Closed -$231K – 54
2019
Q3 		$231K Buy
77,570
+30,000
+63% +$90.7K 0.15% 41
2019
Q2 		$120K Buy
+47,570
New +$208K 0.07% 47

Other funds holding MREO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Birchview Capital's MREO Position: Q4 2019 in Review

Birchview Capital sold out of Mereo BioPharma (MREO) in Q4 2019, closing a stake of 77,570 shares — an estimated $231K sold.

Birchview Capital first reported a position in MREO in Q2 2019 and held it in 2 quarters. The position peaked at $231K in Q3 2019. 14 funds tracked by Wall St. Rank hold MREO as of Q4 2019.

  • Birchview Capital reported no remaining Mereo BioPharma position as of Q4 2019 after selling out during the quarter.
  • Birchview Capital sold 77,570 Mereo BioPharma shares in Q4 2019, an estimated $231K.
  • Birchview Capital first reported a position in Mereo BioPharma in Q2 2019 and held it in 2 quarters.
  • Birchview Capital's Mereo BioPharma position peaked at $231K in Q3 2019.
  • 14 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2019.

Based on Birchview Capital's 13F filing for Q4 2019, filed 12 Feb 2020.